Year:
Language:
Author(s): Lilian Tengborn,inhibidores fibrinoliticos
Format: Document
Descripción del mecanismo de acción de los inhibidores fibrinolíticos y su uso en el tratamiento de trastornos de la coagulación hereditarios, entre ellos las hemofilias A y B, la enfermedad de von Willebrand y los trastornos plaquetarios.
Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by
La principale complication du traitement et de la prévention des hémorragies est le développement d’anticorps inhibiteurs contre le facteur VIII
The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A
The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A
El desarrollo de anticuerpos inhibidores del factor VIII terapéutico (FVIII) en hasta el 40% de las personas con hemofilia A
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Traditional Chinese Los
